Treating the side-effects of the pandemic

Report this content

8 out of 10 are suffering from at least one type of musculoskeletal pain. In fact, it is the leading contributor to disability worldwide. In the pandemic, back and neck pain as a result of more sedentary everyday lives have become growing health issue. Navamedic is re-launching ThermaCare® to make people aware of this drug-free alternative for pain relief.

Musculoskeletal pain is often a result of muscle tension and overexertion, psychological stress or working postures, often in combination with a sedentary lifestyle. Low back pain is extremely common, affecting 30-40% of adults in the general population at any given time. Prevalence is in the range of 15-20% for neck pain and for shoulder pain. The pandemic has led to an increase in back and neck pain.

“There are several reasons for this. Firstly, when working from home, people are moving less than they normally do. Daily and varied physical activity is key to both prevent and recover from musculoskeletal pain. Secondly, psychological stress has increased during the pandemic which may result in neck, shoulder, and back pain. Finally, working from home in a less ergonomic setup in the kitchen or living room, may over time result in musculoskeletal pain,” says Astrid T. Bratvedt, Chief Scientific Officer.

Navamedic have re-launching ThermaCare® this spring with a new communication concept and websites in Norway, Sweden, Denmark, Finland, and the Netherlands. ThermaCare® is an effective and long-lasting pain relief for muscle and joints, using heat and no drugs. The product is developed for fast relief by providing up to 16 hours of effective pain relief, helping people to stay active in their everyday life.   

“Musculoskeletal pain is a big health issue affecting quality of life for the vast majority of the population. As a health issue, it deserves more attention, and we have seen the need for more insights and knowledge. On the ThermaCare® website we will provide articles and interviews on this important subject, as well as information about ThermaCare as an effective and drug-free pain relief,” Astrid T. Bratvedt concludes.

For more information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Phone: +47 951 78 680

E-mail: kathrine@navamedic.com

About ThermaCare®

ThermaCare® is a clinically proven medical device, using unique technology to deliver effective, long lasting pain relief for up to 16h. When the exact mix of components (iron, carbon, water, salt) are exposed to oxygen it creates an exothermic reaction, producing heat with a constant temperature of 40°C for 8h. The constant heat blocks pain signals to the brain, resulting in effective pain relief for 8h while wearing + another 8h after removal. Applying heat relaxes sore muscles and increases blood circulation which allows more oxygen and nutrients to the damaged tissue. ThermaCare® comes in two variants, one for the lower back and one for neck and shoulder. For more information, please visit www.thermacare.no

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

Tags:

Subscribe

Media

Media

Documents & Links

Quotes

Musculoskeletal pain is a big health issue affecting quality of life for the vast majority of the population. As a health issue, it deserves more attention, and we have seen the need for more insights and knowledge. On the ThermaCare® website we will provide articles and interviews on this important subject, as well as information about ThermaCare as an effective and drug-free pain relief
Astrid T. Bratvedt